<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.cancernetwork.com/view/fda-grants-rmat-designation-to-iscib1-in-advanced-melanoma</loc>
      <lastmod>2026-11-20T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T19:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants RMAT Designation to iSCIB1+ in Advanced Melanoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/mitochondrial-genetic-variation-as-a-novel-predictor-of-graft-versus-host-disease-after-stem-cell-transplantation-in-myelodysplastic-neoplasms</loc>
      <lastmod>2026-11-20T18:29:34.815Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T18:29:34.815Z</news:publication_date>
        <news:title><![CDATA[Mitochondrial Genetic Variation as a Novel Predictor of Graft-versus-Host Disease After Stem-Cell Transplantation in Myelodysplastic Neoplasms]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/car-t-cell-induced-interferon-gamma-enhances-mhc-class-i-expression-and-sensitizes-neuroblastoma-to-tcr-engineered-t-cell-therapy</loc>
      <lastmod>2026-11-20T18:21:54.716Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T18:21:54.716Z</news:publication_date>
        <news:title><![CDATA[CAR T Cell-induced Interferon Gamma Enhances MHC Class I Expression and Sensitizes Neuroblastoma to TCR-engineered T Cell Therapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/testosterone-therapy-shows-no-added-progression-risk-in-active-surveillance-pca</loc>
      <lastmod>2026-11-20T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sac-tmt-meets-os-end-point-in-pretreated-gastroesophageal-adenocarcinoma</loc>
      <lastmod>2026-11-20T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T15:00:00Z</news:publication_date>
        <news:title><![CDATA[Sac-TMT Meets OS End Point in Pretreated Gastroesophageal Adenocarcinoma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/when-to-pause-or-stop-therapy-in-advanced-rcc</loc>
      <lastmod>2026-11-20T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:05:00Z</news:publication_date>
        <news:title><![CDATA[When to Pause or Stop Therapy in Advanced RCC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sequencing-strategies-for-limited-volume-metastatic-rcc</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Sequencing Strategies for Limited-Volume Metastatic RCC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/younger-fitter-aml-populations-may-not-need-intensive-chemotherapy</loc>
      <lastmod>2026-11-20T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-20T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Younger, Fitter AML Populations May Not Need Intensive Chemotherapy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/factors-influencing-exercise-behavior-in-patients-with-breast-cancer-during-adjuvant-therapy-a-qualitative-analysis</loc>
      <lastmod>2026-11-19T22:00:03.057Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T22:00:03.057Z</news:publication_date>
        <news:title><![CDATA[Factors Influencing Exercise Behavior in Patients With Breast Cancer During Adjuvant Therapy: A Qualitative Analysis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/a-new-era-of-personalized-cancer-therapeutics-at-esmo</loc>
      <lastmod>2026-11-19T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:00:00Z</news:publication_date>
        <news:title><![CDATA[A New Era of Personalized Cancer Therapeutics at ESMO]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/fda-grants-priority-review-to-sonesitatug-vedotin-in-pretreated-cldn18-2-gastric-gej-cancers</loc>
      <lastmod>2026-11-19T15:45:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:45:00Z</news:publication_date>
        <news:title><![CDATA[FDA Grants Priority Review to Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastric/GEJ Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/bellwave-program-for-nemtabrutinib-discontinued-after-phase-3-cll-sll-trial</loc>
      <lastmod>2026-11-19T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:30:00Z</news:publication_date>
        <news:title><![CDATA[BELLWAVE Program for Nemtabrutinib Discontinued After Phase 3 CLL/SLL Trial]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/et-adherence-raises-cardiometabolic-risk-improves-survival-in-hr-breast-cancer</loc>
      <lastmod>2026-11-19T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:00:00Z</news:publication_date>
        <news:title><![CDATA[ET Adherence Raises Cardiometabolic Risk, Improves Survival in HR+ Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/bhv-1530-shows-responses-in-fgfr3-altered-urothelial-and-head-and-neck-cancers</loc>
      <lastmod>2026-11-19T14:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T14:00:00Z</news:publication_date>
        <news:title><![CDATA[BHV-1530 Shows Responses in FGFR3-Altered Urothelial and Head and Neck Cancers]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/ascent-04-sacituzumab-govitecan-plus-pembrolizumab-in-first-line-pd-l1-positive-metastatic-tnbc</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[ASCENT-04: Sacituzumab Govitecan Plus Pembrolizumab in First-Line PD-L1–Positive Metastatic TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/clinical-scenario-treatment-selection-at-first-relapse-in-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Scenario: Treatment Selection at First Relapse in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/clinical-scenario-celmod-selection-after-car-t-cell-and-bispecific-antibody-therapy-in-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Scenario: CELMoD Selection After CAR T-Cell and Bispecific Antibody Therapy in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/ascent-03-and-tropion-breast02-comparing-adc-efficacy-safety-and-treatment-considerations-in-metastatic-tnbc</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[ASCENT-03 and TROPION-Breast02: Comparing ADC Efficacy, Safety, and Treatment Considerations in Metastatic TNBC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/positioning-celmods-alongside-car-t-cell-therapy-and-bispecific-antibodies-in-relapsed-refractory-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Positioning CELMoDs Alongside CAR T-Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/recognizing-menin-inhibitor-differentiation-syndrome-as-an-aml-class-effect</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Recognizing Menin Inhibitor Differentiation Syndrome as an AML Class Effect]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/clinical-scenario-celmod-selection-before-car-t-cell-therapy-in-multiple-myeloma</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Clinical Scenario: CELMoD Selection Before CAR T-Cell Therapy in Multiple Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/sno-2026-shows-lasting-responses-ongoing-research-for-safusidenib</loc>
      <lastmod>2026-11-18T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:00:00Z</news:publication_date>
        <news:title><![CDATA[SNO 2026 Shows Lasting Responses, Ongoing Research for Safusidenib]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.cancernetwork.com/view/how-should-car-t-and-bispecifics-be-sequenced-in-multiple-myeloma-</loc>
      <lastmod>2026-11-18T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>CancerNetwork</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:00:00Z</news:publication_date>
        <news:title><![CDATA[How Should CAR T and Bispecifics Be Sequenced in Multiple Myeloma?]]></news:title>
      </news:news>
	</url></urlset>